Cullinan Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced its participation in the following upcoming investor conferences: Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D.

GlobeNewsWire • 16 hours ago

Cullinan Therapeutics: Thesis Strengthening For This T-Cell Engager Specialist

Cullinan Therapeutics is rated a Buy, driven by a robust T-cell engager pipeline, savvy management, and a strong $430M+ cash position. CLN-049 (FLT3xCD3) shows ~30% CR rates in AML, with broad applicability, favorable safety, and a clear accelerated approval path via single-arm study. A clear path to market for CLN-049 and regulatory precedent set by predecessors in AML increase the attractiveness of this setup, along with long-lived IP.

Seeking Alpha • Feb 23, 2026

Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Seeking Alpha • Feb 19, 2026

Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit

CAMBRIDGE, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D.

GlobeNewsWire • Feb 18, 2026

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026

CAMBRIDGE, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D.

GlobeNewsWire • Feb 5, 2026

Cullinan Therapeutics: Cash-Rich Biotech With Multiple Value Drivers

Cullinan Therapeutics is a cash-rich clinical-stage biotech with great autoimmune and AML T-cell research, which has promising catalysts for 2026. CGEM also partnered for zipalertinib, which is nearing NDA completion in Q1 2026. I believe this program alone could quickly unlock considerable shareholder value. Additionally, CGEM's CLN-978 (CD19xCD3) will enter Phase 1 and is progressing well as a potential long-term core value driver post-zipalertinib.

Seeking Alpha • Jan 29, 2026

Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones

Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended Phase 2 dose for CLN-049 pivotal registrational study and initiate combination study in frontline AML in Q4 2026 Zipalertinib rolling NDA submission expected to be complete in Q1 2026 and full enrollment of REZILIENT3 frontline study expected in H1 2026 Preliminary cash and investments of $439.0 million as of December 31, 2025; Runway into 2029 CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today provided a corporate update and shared anticipated business highlights for 2026.

GlobeNewsWire • Jan 8, 2026

Cullinan Therapeutics, Inc. (CGEM) Discusses Initial CLN-049 Results and Development Strategy for AML Applications Transcript

Cullinan Therapeutics, Inc. (CGEM) Discusses Initial CLN-049 Results and Development Strategy for AML Applications Transcript

Seeking Alpha • Dec 9, 2025

Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting

CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31% CR/CRh rate observed at the highest target dose tested to date; initial dose escalation results in 45 patients demonstrate a favorable safety profile across all doses assessed CLN-049 recently granted Fast Track designation by the U.S. FDA Company to host in-person event on Monday, December 8, at 8:00 p.m. ET CAMBRIDGE, Mass.

GlobeNewsWire • Dec 8, 2025

Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CLN-049 for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML).

GlobeNewsWire • Dec 1, 2025